Entering text into the input field will update the search result below

BiondVax Pharmaceuticals Ltd.'s (BVXV) CEO Amir Reichman on Q4 2021 Results - Earnings Call Transcript

Apr. 04, 2022 3:23 PM ETBiondVax Pharmaceuticals Ltd. (BVXV)
SA Transcripts profile picture
SA Transcripts

BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) Q4 2021 Earnings Conference Call April 4, 2022 10:00 AM ET

Company Participants

Kenny Green - Edison Group, IR

Josh Phillipson - Director of Business Development and Investor Relations

Amir Reichman - Chief Executive Officer

Matthias Dobbelstein - Professor at University Medical Center, Gottingen

Kenny Green

Hi everyone. Good day. I would like to welcome all of you to BiondVax's Webinar. My name is Kenny Green from Edison Group and I'm part of the IR team at BiondVax. I would like to remind everyone that this conference call today is being recorded and the recording will be available later today on BiondVax's Investor Relations Web site. Please note that this conference call will contain projections or other forward-looking statements regarding future events or the future performance of the company. These statements are only predictions and BiondVax cannot guarantee that they will in fact occur. BiondVax does not assume any obligation to update that information. Actual events or results may materially differ from those projected. Please see the risks identified in the company's documents filed with the Securities and Exchange Commission.

And now I'd like to hand the call over to Josh Phillipson, Director of Business Development and Investor Relations at BiondVax. Josh, please go ahead.

Josh Phillipson

Thank you, Kenny. I would like to thank everyone for attending this event. I'm pleased to welcome today our two presenters, Amir Reichman, BiondVax's CEO; and Professor Dr. Matthias Dobbelstein, who is a professor at the University Medical Center Göttingen and the fellow at the Max Planck Institute for Multidisciplinary Sciences. Amir will provide a recent business update, including our NanoAb pipeline development collaboration with Max Planck and the UMG. The progress of our in-house preparations for the manufacturing of NanoAb here at our GMP biologics manufacturing facility in Jerusalem. And he'll also provide some financial updates, including the recently announced restructuring, the

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.